Ionis Pharmaceuticals, Inc. (0JDI.L)
| Previous close | 43.43 |
| Open | 42.83 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 42.83 - 42.83 |
| 52-week range | 33.21 - 53.94 |
| Volume | |
| Avg. volume | 351 |
| Market cap | 59.326M |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.03 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Zacks4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIonis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireIonis Publishes 2023 Corporate Responsibility Report
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report details Ionis' relentless passion to create better futures for people touched by serious disease as well as other stakeholders. In 2023, Ionis extended its commitment to corporate responsibility (CR) through the establishment of three strategic pillars with actionable goals. Ionis also committed to continuing to transparently communicate the Company's pr
